MedDataX Logo

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)

NCT ID: NCT04397692

Last Updated: 2022-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-13

Study Completion Date

2020-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this open label, randomized, study is to obtain information on the safety and efficacy of 80 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Nitric Oxide (NO) is a small endogenously produced molecule recognized to play a critical role in the function of several body systems including the vasodilatation of smooth muscle, neurotransmission, regulation of wound healing and inhibition of pathogens. In-vitro studies have shown that NO inhibits the replication cycle of the severe acute respiratory syndrome coronavirus (SARS CoV) in vitro. The suggested mechanisms of actions of NO on SARS are an effect on the fusion between the S protein and its cognate receptor, ACE2, and reduction in viral RNA production in the early steps of viral replication. The primary aim of this feasibility study is to investigate the safety of intermittent NO, delivered via inhalation, in hospitalized patients with COVID-19. The primary endpoint in the study will be time to deterioration of respiratory symptoms determined by escalation to either non-invasive ventilation (NIV), high-flow nasal cannula (HFNC), or intubation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corona Virus Infection COVID-19 SARS-CoV 2 Nitric Oxide Respiratory Disease Pneumonia, Viral Inhaled Nitric Oxide

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

COVID-19 Coronavirus Inhaled Nitric Oxide iNO SARS-coronavirus Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Inhaled NO delivered using LungFit™ in addition to SST

Patients will receive 80 ppm iNO for 40 min 4 times a day using LungFit™ device in addition to the standard of care.

Group Type EXPERIMENTAL

Nitric Oxide delivered via LungFit™ system

Intervention Type DEVICE

Patients will receive inhalations of 80 ppm for 40 min 4 times a day

Standard of care

Control - Standard of care

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nitric Oxide delivered via LungFit™ system

Patients will receive inhalations of 80 ppm for 40 min 4 times a day

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Enrollment within 24 hours of hospital admission of patients diagnosed with COVID-19
* Patients with oxygen saturation less than 93 % on room air
* Shortness of breath, with symptom onset within the previous 8 days.
* Female subjects of childbearing potential should take adequate measures to avoid pregnancy
* Signed informed consent by the subject

Exclusion Criteria

* Patients who are treated with or require high flow nasal cannula, CPAP, intubation, mechanical ventilation, or tracheostomy
* Diagnosis of acute respiratory distress syndrome
* Subjects diagnosed with immunodeficiency, with history of congestive or unstable heart disease, left ventricular dysfunction or myocardial damage, severe pulmonary hypertension and/or unstable hypertension
* Patients receiving drugs that have contraindications with NO.
* Breastfeeding or pregnancy as evidenced by a positive pregnancy test.
* Patients with active pulmonary malignancy or lung transplant
* Patients with a history of frequent epistaxis or significant hemoptysis
Minimum Eligible Age

22 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beyond Air Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ashik Tal, MD

Role: STUDY_DIRECTOR

Beyond Air

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Baptist Health Center for Clinical Research

Little Rock, Arkansas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BAI_COV19_01_US

Identifier Type: -

Identifier Source: org_study_id